Finland vs Türkiye: Reported rate of new cervical cancer cases
Finland
5.28 per 100,000 women
in 2022
Türkiye
5.13 per 100,000 women
in 2017
Finland rank
36th
Türkiye rank
38th
Reported rate of new cervical cancer cases over time
- Finland
- Türkiye
How they compare
Finland currently reports 5.28 per 100,000 women against 5.13 per 100,000 women in Türkiye, a difference of 0.15 per 100,000 women.
Across all 20 years both countries report, Türkiye has been ahead every year.
Finland ranks 36th and Türkiye ranks 38th of 46 countries.
Türkiye has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Finland | Türkiye | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 4.24 per 100,000 women | 5.03 per 100,000 women | 0.784 per 100,000 women | Türkiye |
| 2000s | 4.03 per 100,000 women | 5.28 per 100,000 women | 1.24 per 100,000 women | Türkiye |
| 2010s | 4.51 per 100,000 women | 5.29 per 100,000 women | 0.7849 per 100,000 women | Türkiye |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher reported rate of new cervical cancer cases, Finland or Türkiye?
- Finland, at 5.28 per 100,000 women against 5.13 per 100,000 women in Türkiye as of 2022.
- What is the difference in reported rate of new cervical cancer cases between Finland and Türkiye?
- 0.15 per 100,000 women, with Finland ahead.
- How many years of comparable data are there for Finland and Türkiye?
- 20 years are reported by both, from 1998 to 2017.
- How do Finland and Türkiye rank globally for reported rate of new cervical cancer cases?
- Finland ranks 36th and Türkiye ranks 38th of 46 countries.
- Where does this data come from?
- Global Cancer Observatory (2025) – processed by Our World in Data, published as Reported rate of new cervical cancer cases. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Reported number of new cervical cancer cases per 100,000 women, based on data from cancer registries. Comparisons may be affected by differences in measurement, including screening and diagnosis.